Radioactive particles have been used to treat intracranial tumors for more than 70 years[1]Numerous prospective studies and retrospective analyses have concluded that the therapy is minimally invasive and safe, and the overall incidence of serious complications requiring surgical intervention (removal of hematoma, placement of drainage tube)<1.29%[2]。 Due to the particularity of radioactive particle brachycranial tumor treatment, it needs interdisciplinary physicians, such as neurosurgery, radiotherapy department, physicists and interventionists to complete it jointly. The therapeutic risks and the lack of establishing a standard treatment process have become important factors restricting the application of this technology. Each study reported different evaluations on the efficacy of radioactive particles in the treatment of intracranial tumors, with large differences[3,4,5,6,7,8,9,10]The reason is that different researchers have different criteria and surgical methods for selecting patients, and there is a general lack of individualized target areas and prescription dose standards according to different types of tumors, and even few target area delineation principles and dosimetric descriptions[11,12,13,14,15]。 Therefore, from the perspective of scientific research, a basically unified treatment process should be established.
